Genes for hereditary cancer:
-Colon Cancer such as APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLE, POLD1 and SMAD4 genes.
-Breast Cancer genes such as ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK1, CHEK2, FANCA, FANCM, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51B, RAD51C, RAD51, RAD51.
-Pancreatic Cancer genes such as ATM, BRCA1, BRCA2, CDKN2A, FANCA, FANCM, MEN1, MLH1, MSH2, (MSH6), PALB2 and STK11 genes
-Ovarian Cancer genes BARD1, BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, RAD51C, RAD51D and TP53
-Gastric Cancer genes CDH1 and FANCA.
-Melanoma genes such as CDK4, CDKN2A, PTEN and TP53.
-Endometrial Cancer genes such as EPCAM, FANCA and MLH1.
-Endocrine Cancer genes (Familial Adenomatous Polyposis, Multiple endocrine neoplasia Type 1) such as APC, MEN1, RET and VHL.
-Prostate Cancer genes such as ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, PALB2 and PMS2.
-For Lynch syndrome such as EPCAM, MLH1, MSH2, MSH6 and PMS2.
The latest international guidelines (ASCO, ESMO, NCCN and American Society of Breast Surgeons) strongly recommend, instead of BRCA1/2 only, the use of multi-gene panels for a better coverage of the gene variants associated with an increased risk of breast, prostate, colon, pancreatic, ovarian cancer etc.